Introduction
As a consequence of long-term treatment with L-DOPA, the most effective drug to alleviate motor symptoms in Parkinson's disease (PD), patients develop L-DOPA-induced dyskinesia (LID). This motor disorder can be completely disabling for the patient, sometimes reducing quality of life even more than PD itself. In spite of a large number of clinical trials for finding an efficient therapy to reduce LID, the only currently available antidyskinetic drug so far, is the anti-influenza agent amantadine (Fox, 2013) . Unfortunately, prescription of amantadine raises some controversy about its long-term antidyskinetic efficacy (Thomas et al., 2004; Wolf et al., 2010) .
Serotonin (5-HT)-based therapies have been extensively investigated in an attempt to find efficacious antidyskinetic drugs. Indeed, numerous 5-HT agonists have been shown to improve dyskinesia, although not always without worsening the antiparkinsonian effect (Bibbiani et al., 2001; Dupre et al., 2007; Kleedorfer et al., 1991) . For example, sarizotan, a 5-HT 1A receptor agonist, improves dyskinesia in macaque (Gregoire et al., 2009 ) and rat models (Gerlach et al., 2011a) . However, it failed in a III-phase clinical trial on PD patients (Goetz et al., 2007) due to the fact that sarizotan did not counteract LIDs better than placebo. Also, a single dose of eltoprazine, a 5-HT 1A/B -receptor agonist, has recently shown antidyskinetic effects in a placebo-controlled phase I/IIa study (Svenningsson et al., 2015) though no data are yet available about its long treatment efficacy.
In this regard, buspirone, a partial agonist of 5-HT 1A receptors (Peroutka, 1988) has antidyskinetic properties not only in 6-hydroxydopamine (6-OHDA) lesioned rats (Aristieta et al., 2012; Azkona et al., 2014; Dekundy et al., 2007; Eskow et al., 2007; Gerlach et al., 2011b) but also in open-label trials performed in humans (Bonifati et al., 1994; Kleedorfer et al., 1991; Politis et al., 2014) . Interestingly, buspirone, apart from being a partial agonist for 5-HT 1A heteroreceptors, behaves as a full agonist for 5-HT 1A -autoreceptors (Sussman, 1998) in the dorsal raphe nucleus (DRN) inhibiting the serotonergic neuron firing activity (VanderMaelen et al., 1986) . Also, it is important to mention that, although buspirone has affinity mainly for 5-HT 1A receptors, it also acts as an antagonist for D 2 and D 3 dopamine receptors (Bergman et al., 2013; Dhavalshankh et al., 2007; McMillen et al., 1983) . In fact, buspirone reduces graft-induced dyskinesia in a rat model of PD by a mechanism which is independent from activation of either pre-or post-synaptic 5-HT 1A receptor (Shin et al., 2012) . All these peculiarities could help to explain why buspirone is an efficacious antidyskinetic drug and make it interesting to figure out the target through what buspirone elicits its antidyskinetic effect.
The subthalamic nucleus (STN) is the only glutamatergic nucleus of the basal ganglia and exerts the principal excitatory effect on the output nuclei of the basal ganglia, playing a critical role in the motor circuit. Local infusion of a stimulatory 5-HT 2C -receptor agonist into the STN induces orofacial dyskinesia in rat (Eberle-Wang et al., 1996) . Moreover, we reported that when the STN is lesioned the antidyskinetic effect of buspirone is decreased (Aristieta et al., 2012) . Therefore, the aim of this study was to investigate the effect induced by buspirone on the STN neuronal activity not only in brain slices but also in anaesthetized control and 6-OHDA lesioned rats chronically treated with saline or L-DOPA.
Materials and methods

Animals
Female Sprague-Dawley rats weighing 200-280 g for in vivo experiments and male Sprague-Dawley rats weighing 50-75 g for ex vivo experiments were housed in groups of six with free access to food and water in environmentally controlled conditions (20 ± 2°C; 65-70% of relative humidity and a 12 h:12 h light/dark cycle). Every effort was made to minimize animal suffering, to use the minimum number of animals per group and experiment and to utilize alternatives to in vivo techniques if available. Experimental procedures were approved by the Local Ethical Committee of the University of Basque Country (UPV/ EHU, CEBA/185/2011), following European (2010/63/UE) and Spanish (RD 1201 (RD /2005 regulations for the care and use of laboratory animals.
2.2. 6-OHDA lesion and L-DOPA treatment 6-OHDA lesions were performed according to our established protocols (Aristieta et al., 2012; Miguelez et al., 2011) . Rats were pretreated 30 min before anesthesia with desipramine (25 mg/kg, i.p.) in order to preserve the noradrenergic terminals. Then, rats were anesthetized with isoflurane inhalation and placed in the stereotaxic frame (David Kopf® Instruments). Lesions were performed by two injections of 6-OHDA of 7.5 μg and 6 μg, respectively (3.5 μg/μl saline with 0.02% ascorbic acid) in the right medial forebrain bundle: 2.5 μl at anteroposterior (AP) −4.4 mm, mediolateral (ML) +1.2 mm and dorsoventral (DV) −7.8 mm, relative to bregma and dura with the toothbar set at −2.4, and 2 μl at AP − 4.0 mm, ML + 0.8 mm, and DV −8 mm, with toothbar at + 3.4 (Paxinos and Watson, 1986) . Sham animals were similarly treated but instead of 6-OHDA received vehicle. For the administration of the neurotoxin a 10 μl-Hamilton syringe was used and the infusion rate was 1 μl/min. Prior to the administration, the toxin was kept protected from light and in ice. Two weeks later, the severity of the 6-OHDA lesion was evaluated by rotational behavior over 90 min after d-amphetamine (3 mg/kg, i.p.) administration, and only severely lesioned animals were selected for this study (more than 5 full-body ipsilateral turns/min).
Rats were divided in four different groups depending on the lesion and pharmacological treatment followed: control, sham L-DOPA, 6-OHDA lesioned and 6-OHDA lesioned plus L-DOPA (dyskinetic) rats. Animals were treated chronically over 3 weeks with saline in the control and 6-OHDA lesion groups; or with L-DOPA (6 mg/kg + benserazideHCl (12 mg/kg s.c.) in sham L-DOPA and the dyskinetic groups. On day 21, the dyskinetic movements were scored as described by Miguelez et al. (2011) . All 6-OHDA lesioned animals chronically treated with L-DOPA developed severe dyskinetic movements that reached the peak between 40 and 80 min after a single injection of L-DOPA (Fig. 1A) . Tyrosine hydroxylase (TH)-immunostaining was used to examine the degree of dopaminergic denervation in the striatum and the substantia nigra following the methodology described by Miguelez et al. (2011) and in all cases the loss of striatal DA fibers was N90% (Fig. 1B) .
Electrophysiological recordings
Ex vivo recordings
Male Sprague Dawley rats (50-75 g) were anesthetized with chloral hydrate (400 mg/kg, i.p.) and sacrificed by decapitation. The brain was rapidly dissected out and placed in ice-cold cutting solution containing (in mM): 20 NaCl, 2.5 KCl, 0.5 CaCl 2 , 7 MgCl 2 , 1.25 NaH 2 PO 4 , 85 sucrose, 25 D-glucose and 60 NaHCO 3 , saturated with 95% O 2 /5% CO 2 . The cerebellum was removed and brain hemispheres were separated along the inter-hemispheres line. Parasagittal brain slices (300-350 μm thick) containing the STN, identified as a lens-shaped dense patch located medial to the internal capsule, were cut and immediately placed in the artificial cerebrospinal fluid (aCSF) composed of (mM) 126 NaCl, 2.5 KCl, 1.2 MgCl 2 , 2.4 CaCl 2 , 1.2 NaH 2 PO 4 , 11.1 D-glucose, 21.4 NaHCO 3 , 0.1 ascorbic acid, and saturated with 95% O 2 /5% CO 2 at 33°C. After at least one hour resting at 33°C, the slice was submerged in a slice chamber (0.5 ml) mounted on the microscope stage and superfused (2.5-3 ml/min) with the aCSF bathing solution at 31°C. STN neurons were visually identified using an upright microscope with infrared optics (Eclipse E600FN, Nikon®) equipped with a 40 × water-immersion objective. Patch electrodes were pulled from borosilicate glass capillaries (World Precision Instruments) on a two-stage puller (PC-10, Narishige) to a pipette resistance of 3-5 MΩ. Recordings were made with an Axopatch 200B amplifier and digitized with a Digidata 1322A (Axon Instruments®). To accurately examine spontaneous firing in STN neurons, pipettes were filled with aCSF and recordings were performed in the minimally invasive cell-attached loose patch configuration (20-30 mΩ seal resistance). Data were low-pass filtered at 5 kHz before being digitized at a rate of 10 kHz. Acquisition and all subsequent analysis were carried out with Clampex 10.4. Firing rate histograms were generated by integrating action potential discharge in 10 s bins (Fig. 1C) . 54 cells fired spontaneously and regularly at 13 ± 1 Hz. Only 5 neurons fired in burst mode and 4 cells remained silent. This proportion of regularly firing neurons strongly resembles what has been described in the literature (98%) for ex vivo STN cells (Wilson et al., 2004) . Also, an increase in the temperature from 31 to 35°C induced a reversible increase in the average frequency of spontaneous firing rate from 13 ± 4 Hz to 19 ± 7 Hz (n = 6; paired t test, p b 0.05) (Fig. 1D ) as it has been described for this nucleus (Heida et al., 2008) . All drugs were applied in the perfusion solution in known concentrations.
In vivo recordings
All STN neuron electrophysiological recordings in vivo were performed as described by Morera-Herreras et al. (2011) , twenty-four hours after the last saline or L-DOPA injection. Rats were anesthetized with urethane (1.2 g/kg, i.p.) and placed in a stereotaxic frame with its head secured in a horizontal orientation. The recording electrode was lowered into the right STN (relative to bregma and dura: AP −3.7 mm, ML −2.5 mm and DV −7/−8.5 mm). The extracellular signal from the electrode was amplified with a high-input impedance amplifier and was monitored on an oscilloscope and on an audio monitor. All recorded STN neurons exhibited a biphasic waveform and a spike width of 1.0 to 1.5 ms (Hollerman and Grace, 1992) . Neuronal spikes were digitized using computer software (CED micro 1401 interface and Spike2 software, Cambridge Electronic Design). The basal firing rate was recorded for 5 min.
Local injection of buspirone close to the STN neuron which was being recorded was performed as described by Ruiz-Ortega and Ugedo (1997) . Pressure pulses (50-150 ms) were applied to a calibrated pipette, glued adjacent to a recording micropipette, containing buspirone (0.25 M) dissolved in Dulbecco's buffered saline solution (NaCl, 136.9 mM; KCl, 2.7 mM; NaH 2 PO 4 , 8.1 mM; KH 2 PO 4 , 1.5 mM; MgCl 2 , 0.5 mM and CaCl 2 , 0.9 mM, pH 7.4). The volume of each ejection pulse was measured by monitoring the meniscus movement in the calibrate pipette.
At the end of each electrophysiological experiment, a Pontamine Sky Blue mark was deposited for posterior verification of the recording site using neutral red staining. Only cells recorded within the STN were included in this study (Fig. 1E) . The firing parameters of STN neurons were analyzed off-line using Spike2 software. The following parameters were calculated: firing rate, coefficient of variation and firing pattern. The different firing patterns could be analyzed according to the method described by Kaneoke and Vitek (1996) (Fig. 1F) . The analyzed spiketrains lasted more than 120 s and contained at least 300 spikes. 
Drugs
Drugs used in this study were: 6-OHDA (3.5 μg/μl) dissolved in MiliQ water containing 0.02% ascorbic acid; desipramine hydrochloride (25 mg/kg i.p.), amphetamine sulfate (3 mg/kg i.p.), chloral hydrate, L-DOPA (6 mg/kg s.c.), benserazide-HCL (12 mg/kg s.c.), serotonin hydrochloride (5-HT, 30 μM ex vivo), buspirone hydrochloride (4 and 8 mg/kg, i.p. in vivo; 10 and 30 μM ex vivo) and WAY-100635 maleate salt (0.5 and 1.5 mg/kg, i.p. in vivo; 1 μM ex vivo) from Sigma-Aldrich disolved in 0.9% saline or Dulbecco for in vivo experiments and dissolved in aCSF for ex vivo experiments. Fast synaptic transmission blockers were gabazine (5 μM) and DNQX (20 μM) from Tocris and D-AP5 (50 μM) from Abcam. Urethane was dissolved in MiliQ water.
Statistical analysis of data
Experimental data were analyzed using the computer program GraphPad Prism (v. 5.01, GraphPad Software, Inc). The electrophysiological data were analyzed by paired t test when two situations were compared and one-way analysis of variance (ANOVA) followed by post-hoc comparisons using the Newman Keuls to compare different groups. The firing pattern of STN neurons was analyzed using Fisher's exact test. The level of statistical significance was set at p b 0.05. Data are presented as group means ± standard error of the mean (SEM).
Results
Characterization of 5-HT and buspirone-effects on STN neurons in control brain slices
First of all, to validate our STN preparations we decided to study the well known effect induced by 5-HT on STN neurons. For that purpose, 41 neurons were studied before and after a bath application of 5-HT. The majority of these cells (n = 39) spontaneously fired regular action potentials at a mean rate of 11 ± 1 Hz. Only two cells did not show spontaneous firing. As it has been previously described (Stanford et al., 2005 ) not all of these 41 neurons responded in the same way to the perfusion with 5-HT (30 μM). The main effect induced by 5-HT was a reversible increase in STN-neuron firing rate in 31 out of 41 neurons, a percentage also observed by others (Stanford et al., 2005) . On average, firing rates increased moderately and in a concentrationdependent manner in the presence of 5-HT ( Fig. 2A) . 5-HT (30 μM) increased the firing rate by 253 ± 30% (n = 29) in these cells. 5-HT induced firing activity on two silent cells but the magnitude of the effect could not be quantified as the percentage change had to be calculated according to the basal firing value. The excitatory effect was not mediated through 5-HT 1A -receptor activation since perfusion with the 5-HT 1A antagonist, WAY-100635 (1 μM), for at least 10 min had no effect on basal firing rate or on the excitatory responses induced by 5-HT (30 μM) (n = 5, paired t test p N 0.05) (Fig. 2B) . Only in two cases, the neuron recorded responded to 5-HT (30 μM) with a decrease in the firing rate and in 3 out of 41 no effect was observed. Interestingly, five cells responded in a robust and repeatable biphasic manner (Fig. 2C ). In these cells 5-HT induced firstly a significant 64 ± 16% reduction of the firing rate (paired t test, p b 0.01) immediately followed by an increase of the firing rate above the basal frequency (54 ± 12%, p b 0.05, n = 5). Subsequent WAY-100635 (1 μM) perfusion specifically and completely abolished the inhibitory component of the biphasic response indicating that it was mediated by the activation of the 5-HT 1A receptor (Fig. 2D) . The excitatory component did not change after WAY-100635 application.
We have previously shown that a STN lesion decreases the antidyskinetic effect of buspirone in vivo (Aristieta et al., 2012) . Here, we considered to investigate the possible direct effect of buspirone on STN-neurons in a more isolated model such as brain slices. In our study, buspirone was tested in 51 STN neurons where it exerted a limited and variable effect depending on the cell recorded. In fact, bath application of buspirone (10-30 μM) failed to induce any effect in 31 of the studied cells (61%). On the other hand, in 14 out of 51 studied cells, buspirone induced a significant 45 ± 7% inhibition of the firing rate (n = 14). Different concentrations of buspirone were used, 10 μM and 30 μM, but since the magnitude of the inhibitory effect was similar in both sets of experiments (t test, p N 0.05), all data were pooled together. The inhibitory effect exerted by buspirone was slow to wash out but easily reversed and prevented by a bath perfusion of the slice with WAY-100635 (4 ± 15% change, paired t test; p b 0.05, n = 6). A second application with buspirone failed to alter the basal firing rate in the presence of WAY-100635 (1 μM) (− 6 ± 3% change, p N 0.05; n = 4) ( Fig. 3A and B) . Buspirone rarely induced an excitatory effect (3 out of 51 cells), increasing the firing rate by 54 ± 12% (Fig. 3C and E) . Interestingly, buspirone also exerted an unusual biphasic response in 3 STNneurons characterized by an excitatory response (78 ± 22%) immediately followed by a 56 ± 21% inhibitory one ( Fig. 3D and E) . Altogether, whilst 5-HT main effect was excitation (31/41), buspirone's key effect was inhibition only in 14 out of 51 studied neurons (Fig. 3F ).
To better characterize the buspirone effect, a series of supplementary experiments were performed in the presence of fast synaptic transmission blockers consisting in the GABA A receptor antagonist gabazine (5 μM), the selective NMDA receptor antagonist D-AP5 (50 μM) and the AMPA and kainate receptor antagonist DNQX (20 μM). 23 STN neurons were recorded in the presence of the fast synaptic transmission blockers. These neurons showed a regular firing frequency (11.4 ± 1.5 Hz) which slightly changed to 12.5 ± 1.7 Hz (paired t test, n = 19, p b 0.05) after 5 min of bath perfusion with the blockers. As shown in the Supplementary Fig. 1 , all effects induced by buspirone (inhibition, stimulation and biphasic response) were almost completely blocked by the synaptic transmission blockers perfusion.
Characterization of buspirone-effect on STN neurons in control anesthetized rats
We studied the effect of buspirone on subthalamic neuronal activity in anesthetized rats. For that purpose, basal electrophysiological parameters of STN neurons (n = 23) were recorded over a period of 5 min before and, at least, 20 min after the administration of buspirone (4 and 8 mg/kg i.p.) (Fig. 4) . All cells recorded displayed most characteristic firing properties of STN neurons described in our previous publications (Aristieta et al., 2012; Morera-Herreras et al., 2011) (Table 1) . However, the proportion of busty cells was high compared to our previous studies what may be attributed to gender differences as shown in PD patients (Mrakic-Sposta et al., 2008) . In control rats, buspirone administration decreased the firing rate of every STN neuron tested in a dose related manner. Thus, buspirone 4 mg/kg reduced the firing rate by 35 ± 7% (p b 0.01, paired t test; n = 12) ( Fig. 4A and B) and 8 mg/kg produced an inhibition of 76 ± 5% with respect to the basal values (p b 0.001, paired t test; n = 11) ( Fig. 4B and C) . This inhibitory effect was slowly reversed to basal levels after 60 min. Buspirone also modified the coefficient of variation of the cells, making them more irregular, (54% for 4 mg/kg and 63% for 8 mg/kg; p b 0.01; paired t test) (Fig. 4D) . Firing pattern of STN neurons was also significantly altered after buspirone administration, decreasing the percentage of STN neurons discharging in burst (p b 0.001; χ2 test = 13.33 and χ2 test = 51.11, for 4 and 8 mg/kg, respectively) (Fig. 4F) . Also, buspirone 8 mg/kg, but not 4 mg/kg, induced a random pattern in a 30% of the studied population (Fig. 4F) . We next attempted to reverse the inhibitory effect induced by buspirone with a 5-HT 1A receptor antagonist. For this purpose, WAY-100635 (0.5 and 1.5 mg/kg i.p.) was administered 10-15 min after the administration of buspirone (8 mg/kg i.p.). After a dose of 8 mg/kg of buspirone, 1.5 mg/kg but not 0.5 mg/kg of WAY-100635 (i.p.), fully reversed the inhibitory effect induced by buspirone in the firing frequency (reversal effect 111 ± 5%; F (3,9) = 14.97, p b 0.0001, one-way ANOVA; n = 4) ( Fig. 4B and C) . Furthermore, the highest dose of WAY-100635 also reversed the effect exerted by buspirone on the regularity of these neurons, bringing back the coefficient of variation to basal values (41 ± 5%; F (3,9) = 7.58, p b 0.01, one-way ANOVA) (Fig. 4D) . The firing pattern of these neurons returned to basal conditions after the administration of WAY-100635 (p b 0.001, Fisher exact test) (Fig. 4F) . Next, we applied lower doses of WAY-100635 (0.1 mg/kg, i.p.) prior to buspirone administration (15 min). In this case, WAY-100635 had no effect on STN firing frequency but completely blocked the inhibitory effect of buspirone (F (2,14) = 1.22, n = 5; p N 0.05, one-way ANOVA) ( Fig. 4C and D) . However, WAY-100635 did not block the effect of buspirone on the coefficient of variation, which became more irregular after buspirone administration (70 ± 9%) (F (2,8) = 3.47, p b 0.05, one-way ANOVA) (Fig. 4D) . Interestingly, the administration of WAY-100635 turned neurons more bursty (60% before and 100% after the administration of WAY-100635) as previously shown . This modification was reverted after buspirone was applied (bursty cells: 40%) (p b 0.01, Fisher exact test) (Fig. 4F) .
To better characterize buspirone effect, buspirone was injected into the STN near to the STN neuron that was being recorded. In this case buspirone caused inhibition only in 2 out of 7 recorded neurons (Fig. 5). 3.3. Characterization of buspirone-effect on STN neurons in 6-OHDA lesioned and dyskinetic rats Next we studied the effect of buspirone in three groups with different conditions: sham L-DOPA (n = 6), 6-OHDA lesioned (n = 5) and 6-OHDA lesioned plus L-DOPA (n = 7) rats. Firstly, the spontaneous electrical activity of STN neurons from these rats was recorded and, as we and others have previously described, we found that the STN becomes hyperactive after dopamine depletion (Aristieta et al., 2012; Bergman et al., 1994; Hassani et al., 1996; Morera-Herreras et al., 2011) . As described in Table 1 , firing rate in STN neurons from both 6-OHDA lesioned and dyskinetic rat groups as well as the coefficient of variation of dyskinetic rats were significantly higher than in the control rat group (F ( 3,47) = 10.86 and F (3, 47 ) = 45 respectively; p b 0.001, one-way ANOVA). Firing pattern in 6-OHDA lesioned and dyskinetic rats was also different than that found in the control group (p b 0.01, χ2 test = 8.33; p b 0.05, χ2 test = 8.42 respectively).
In sham L-DOPA rats, in the same way as in control rats, we observed that buspirone administration (8 mg/kg i.p.) induced a 58 ± 12% decrease on the firing rate (paired t test, p b 0.01; n = 6) (Fig. 6) . There was also a decrease in the regularity of these neurons, shown by an increase in the coefficient of variation from 52 ± 10% in basal conditions to 98 ± 12% after buspirone administration (paired t test, p b 0.05; n = 6) (Fig. 6D) . In this group of rats the amount of neurons discharging in burst did not change after buspirone administration, however, a 16% of neurons turned to show a random pattern (p b 0.001, χ2 test = 21.89) (Fig. 6F) .
Interestingly, buspirone (8 mg/kg i.p.) did not modify the firing rate of STN neurons neither in 6-OHDA lesioned rats (before 13.0 ± 1.1 Hz vs after buspirone 12.5 ± 1.3 Hz; n = 5) ( Fig. 5B and C) nor in dyskinetic rats (before 14.7 ± 2.8 Hz vs after buspirone 19.4 ± 4.6 Hz; n = 7) ( Fig. 5B and E) . Also, the neuron regularity from both groups remained unchanged, as it is shown by the absence of change in the coefficient of variation (lesioned, 42 ± 7% vs 53 ± 12% and dyskinetic 130 ± 12% vs 139 ± 10%, before vs after buspirone) (Fig. 5D) . On the contrary, bursting pattern of STN neurons decreased after buspirone administration in 6-OHDA lesioned (before 40% vs after buspirone 20%, p b 0.01, χ2 test = 9.52) and dyskinetic rats (before 57% vs after buspirone 29%; p b 0.001, χ2 test = 19.79) (Fig. 5F ).
Discussion
We have previously shown that the 5-HT 1A receptor agonist buspirone not only improves dyskinesias in a rat model of LID but also reverses some key molecular changes related to these motor complications (Azkona et al., 2014) . Interestingly, these important effects were attenuated when the STN was lesioned (Aristieta et al., 2012) . Here, we show that buspirone reduces the firing rate of STN neurons through the activation of 5-HT 1A receptors by a complex mechanism. Buspirone ex vivo only caused inhibition in a small population of neurons while in vivo, when systemically applied, all recorded neurons from control rats were clearly inhibited. Furthermore, in 6-OHDA-lesioned rats chronically treated or not with L-DOPA, buspirone completely failed to induce any effect on STN activity suggesting that the dopaminergic system is also implicated.
The STN, and in general the basal ganglia, is innervated by 5-HT-rich fibers coming primarily from neurons in the DRN (Di Matteo et al., 2008; Liu et al., 2007; Mori et al., 1985) . It has been shown that not only 5-HT 1A , 5-HT 2C and 5-HT 4 receptor-mRNAs but also the correspondent receptors are expressed in STN cells (Eberle-Wang et al., 1997; Grossman et al., 1993; Maroteaux et al., 1992; Pompeiano et al., 1992; Waeber et al., 1996) . Also, 5-HT 1B/D -receptors are located in terminals of the motor cortex and the external segment of the globus pallidus neurons that project to the STN (Hannon and Hoyer, 2008; Hoyer et al., 2002; Sari et al., 1999). Furthermore, 5-HT depletion, systemic administration of a nonselective 5-HT receptor antagonist as well as lesioning the DRN increase the firing rate of STN neurons Liu et al., 2007) . However, according to the literature, the effects of 5-HT on STN neurons ex vivo are an increase in the firing rate, without changing the firing pattern, through 5-HT 2C and 5-HT 4 receptors activation and also a less frequent inhibition through 5-HT 1A/B receptor activation (Flores et al., 1995; Stanford et al., 2005; Xiang et al., 2005; Shen et al., 2007) . In our hands, 5-HT ex vivo induces a reversible increase in STN-neuron firing rate in a 76% of the studied neurons, in a comparable proportion to the 82% described by Stanford et al. (2005) and in agreement with the inward current described for the 64% of the patch-clamped STN neurons (Shen et al., 2007) . 5-HT induced rarely an inhibitory effect in a 5% of the recorded cells, in a similar way it has been described before. Finally, a 12% of the recorded neurons responded to 5-HT with a biphasic response as the 8% shown previously by Stanford et al. (2005) and in agreement with the biphasic current found in a 19% of STN neurons by Shen et al. (2007) . Furthermore, we have shown here that the inhibitory phase induced by 5-HT is mediated through the activation of the 5-HT 1A receptor as it was prevented by the selective antagonist WAY-100635, compared to what has been shown in those previously cited works where it was blocked using the less selective 5-HT 1A/B receptors antagonist WAY-100135. When we applied buspirone ex vivo it failed to induce any effect in the 61% of the studied neurons and primarily inhibited the firing rate only in a 27% of the studied cells through the activation of the 5-HT 1A receptor. Buspirone also induced an excitatory effect in a 6% and a biphasic effect in another 6% of the recorded cells. These results agree with the fact that 5-HT also induces inhibition in a small population through 5-HT 1A receptor being the inhibitory effect expressed in a selected and scarce group of STN neurons (Stanford et al., 2005) . However, 5-HT, a full agonist, inhibits the STN in only the 5% of the recorded cells, less than the 27% induced by buspirone. This discrepancy could be explained by the probable 5-HT interference co-activating other excitatory receptors (5-HT 2C-4 ) as well, which would eclipse the 5-HT 1A receptor effect, especially when these inhibitory receptors were expressed in lower proportion. Altogether, the STN appears to be a very heterogeneous nucleus composed by a population of neurons which show different responses depending on the array of serotonergic receptors expressed, being the inhibitory response mediated by 5-HT 1A receptors present in a small proportion of neurons.
It has been previously shown that the 5-HT 1A full agonist 8-OH-DPAT administered systemically after 5-HT depletion, or locally administered in the STN in vivo, inhibits STN neuron activity . Here, we show that also buspirone dose-dependently inhibits the firing rate on every STN neuron recorded in control rats through the activation of the 5-HT 1A receptors. As buspirone has been described as a partial agonist at post-synaptic receptors but as a full agonist at DRN 5-HT 1A somatodendritic autoreceptors (Sprouse and Aghajanian, 1988; Valdizan et al., 2010) , collectively this STN inhibition could be attributed to a direct effect mediated by the activation of the postsynaptic 5-HT 1A receptors located in the STN itself or via an indirect effect perhaps via DRN autoreceptors. In this sense, it has been recently shown that either 5-HT 1A -receptor agonists that preferentially activate post-synaptic 5-HT 1A -receptor, such as F15599, or 5-HT 1A -receptor agonist that preferentially activate pre-synaptic 5-HT 1A -receptor like F13714, all reduce LID in animal models of PD (Huot et al., 2015; Iderberg et al., 2015a) . Also, a potent and efficacious pre-and post-synaptic 5-HT 1A receptor agonist, F13640, has been recently demonstrated to be a promising antidyskinetic drug (Iderberg et al., 2015b) . Nevertheless, present findings indicate that buspirone effect on STN neurons involve indirect mechanisms: (1) the application of a supramaximal concentration of buspirone ex vivo, in a preparation that preserves only afferent terminals to the STN, failed to reduce the firing rate in the majority of the recorded cells, (2) ex vivo buspirone effects were almost completely prevented by the presence of fast synaptic transmission blockers and (3) in vivo local injection of buspirone into the STN affects to a small number of recorded STN neurons.
Indeed, an indirect effect mediated by 5-HT 1A receptors in the cortex, globus pallidus, substantia nigra pars compacta, thalamus or DRN cannot be excluded, since the STN receives input from all of these structures that are affected by buspirone (Canteras et al., 1990; DeLong and Wichmann, 2007; Lanciego et al., 2004; Nambu et al., 2002; Parent et al., 2011) . Interestingly, it was already described in 1995 that buspirone at 4 mg/kg i.p. not only reduced glucose metabolism in the cortex, thalamus, globus pallidus and DRN but also in the STN of the rat (Freo et al., 1995) .
Buspirone also reduces 5-HT synthesis rate in various rat brain structures including basal ganglia and the DRN (Okazawa et al., 1999) and totally inhibits DRN neurons (VanderMaelen et al., 1986) . It is important to point out that in anesthetized rats buspirone significantly increases the levels of dopamine in cortex and striatum (Silverstone et al., 2012) whereas, activation of 5-HT 1A -receptors attenuates the increase in extracellular dopamine derived from exogenously administrated L-DOPA in the striatum of 6-OHDA lesioned rats (Kannari et al., 2001) . Moreover, when administered to dyskinetic PD patients, buspirone not only reduces L-DOPA-evoked striatal synaptic dopamine increases but also attenuates LIDs (Politis et al., 2014) . Interestingly, we observed that in 6-OHDA lesioned rats either treated with saline or with L-DOPA (dyskinetic rats) buspirone had no effect on the neuronal activity of the STN. The fact that nigrostriatal pathway must be intact for buspirone to exert its inhibitory effect in the STN suggests that the effect may be mediated by dopamine. In this sense, immunohistochemical studies have demonstrated the presence of both D 1 and D 2 dopamine receptors on STN cells (Bouthenet et al., 1987; Boyson et al., 1986; Flores et al., 1999; Johnson et al., 1994) . Several findings indicate that the response of STN neurons to dopaminergic drugs is altered after dopaminergic denervation of the basal ganglia. Thus, apomorphine, a non selective dopamine receptor agonist, and D 2 dopamine receptor agonists administration induces a decrease in the firing rate of STN neurons in intact rats and do not have effect on 6-OHDA lesioned rats (Hassani and Feger, 1999) . On the other hand, as it has been consistently shown that the 5-HT system is severely affected after degeneration of nigrostriatal dopaminergic neurons, a modulation of this system may be also considered. However, although several studies have observed a reduction of 5-HT 1A receptor binding sites in the DRN of patients with PD (Doder et al., 2003) and in MPTP-treated monkeys (Frechilla et al., 2001 ) no changes have been reported concerning the density of 5-HT 1A receptors in the striatum (Azkona et al., 2014) . According to that, although Wang et al. (2009) reported a severe reduction in 8-OH-DPAT potency in the DRN after a unilateral lesion of the nigrostriatal pathway, we did not observe it in our model .
Conclusions
In conclusion, our results show that buspirone exerts its inhibitory effect through 5-HT 1A receptors by a complex mechanism that may involve the dopaminergic system. We also found that the antidyskinetic effect of buspirone does not imply a direct modulation of the electrical activity of the STN. Dyskinesia is a debilitating motor complication that appears in the majority of the patients that receive chronic treatment with L-DOPA. In spite of numerous efforts to develop a pharmacological treatment, there is not yet any new licensed drug to treat or prevent LIDs better than amantadine which clinical use is limited because of its partial efficacy and some important tolerability issues such as constipation, dizziness and hallucinations (Pahwa et al., 2015) .
It is essential to characterize drug targets to develop new treatments. In this sense the 6-OHDA lesioned rat model has proved to be a useful tool for studying both PD and the side effects resulting from treatment with L-DOPA (Bezard and Carta, 2015; Miller and Beninger, 1991; Schallert et al., 2000; Ungerstedt, 1971) . Our present results show that response to buspirone depends on dopaminergic innervation stressing the importance of animal model to identify new antidyskinetic pharmacological tools.
Supplementary data to this article can be found online at http://dx. doi.org/10.1016/j.expneurol.2015.12.005.
Funding
This work has been supported by grants from the Government of the Basque Country T747-13, the University of the Basque Country (UFI 11/ 32) and the Spanish Government (PI12/00613) co-financed by FEDER. A.S. had a predoctoral fellowship from the University of the Basque Country (UPV-EHU).
Conflicts of interest
The authors declare to have no conflicts of interest.
